In phase I clinical trial, DCs transfected with p53, survivin, and TERT encoding mRNA in combination with mCy (metronomic regimen of cyclophosphamide) has been used in patients with progressive metastatic melanoma to evaluate the feasibility and safety profiling. The gene discussed is BIRC5; the disease is metastatic melanoma.